Your email has been successfully added to our mailing list.

×
0 0 0.00388601036269422 0.00129533678756474 0.00259067357512948 -0.00129533678756485 -0.00518134715025907 -0.00194300518134722
Stock impact report

Early-stage study underway assessing Dicerna's lead candidate in rare liver disorder [Seeking Alpha]

Dicerna Pharmaceuticals, Inc. (DRNA) 
Last dicerna pharmaceuticals, inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dicerna.com
Company Research Source: Seeking Alpha
Early-stage study underway assessing Dicerna's lead candidate in rare liver disorderThe first patient has beendosed in a Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of Dicerna Pharmaceuticals' (DRNA-2.9%) lead candidate, DCR-PHXC, in development for the treatment ofprimary hyperoxaluria (PH), a group of rare inherited liver disorders that leads to kidney failure.The study has two arms: Group A consists of healthy volunteers and Group B patients with PH types 1 and 2.Dosing in Group B will start next quarter.DCR-PHXC is an RNAi therapeutic based on the company'sGalXC platform which enables subcutaneous administration.Now read:Sangamo Therapeutics: Engineering Genomic Solutions For Rare Diseases » Show less Read more
Impact Snapshot
Event Time:
DRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for DRNA alerts
Opt-in for
DRNA alerts

from News Quantified
Opt-in for
DRNA alerts

from News Quantified